“Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s291. https://doi.org/10.25251/skin.7.supp.291.